ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP42-22 Reminder: Self-Administered Drug Coverage for Medicare Members
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါမ့ၤ 25, 2022
လံာ်တီလံာ်မီတဖၣ်ဒီး လံာ်ကွီၣ်ဒိတဖၣ်အစၢတဖၣ်
တၢ်ပာ်ဖျါ 2031 - 2040 လၢ 3273 အစၢတဖၣ်အကျါ
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP43-22 Reminder: Medical Drug Coding for Botulinum Toxins
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါမ့ၤ 25, 2022
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP44-22 Improved Provider Webpage
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါမ့ၤ 25, 2022
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP45-22 First Responder Mental Health Summit: Clinician Awareness Course Friday, June 24
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါမ့ၤ 25, 2022
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP41-22 MHCP Pharmacy Benefit Exclusion for Opdualag™ and paclitaxel protein-bound particles
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါမ့ၤ 25, 2022
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP40-22 Temporary Rate Increase for Personal Care Attendant (PCA) Services
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါမ့ၤ 11, 2022
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP37-22 MHCP Pharmacy Benefit Update – New Drug-Related Prior Authorization (PA) with Quantity Limit (QL) Criteria: VoxzogoTM (vosoritide)
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါမ့ၤ 11, 2022
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP38-22 Updates to Authorization Request with Unlisted or Unspecified Codes
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါမ့ၤ 11, 2022
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP36-22 Commercial Pharmacy Benefit Exclusion for Xolair®
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါမ့ၤ 11, 2022
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP85R1-21 Resolution Process for Providers Serving Minnesota Health Care Programs (MHCP) Members
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါမ့ၤ 11, 2022